Trial investigates once-daily NNC0090-2746 subcutaneous injection for Type 2 Diabetes efficacy and safety

Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. While metformin remains a cornerstone first-line therapy, many patients eventually require additional pharmacotherapy to achieve and maintain adequate glycemic control. Current treatment options often come with limitations in efficacy, safety, or tolerability, driving the continuous search for novel therapeutic agents. This study aims to explore NNC0090-2746 as a potential new adjunct therapy to address these unmet needs in T2D management.

This clinical trial is designed to assess the efficacy, safety, and tolerability of NNC0090-2746 administered as a once-daily subcutaneous (SC) injection. The study duration for the intervention is 12 weeks. Participants are individuals diagnosed with Type 2 Diabetes whose condition is inadequately controlled despite ongoing treatment with metformin. The trial is being conducted in the United States of America (USA), with the primary endpoints focusing on the compound's performance when used as an adjunct to existing metformin therapy.

The provided trial description outlines the study's design and objectives, focusing on the investigation of NNC0090-2746. However, it does not include any reported efficacy, safety, or tolerability results from the trial. Therefore, specific numerical findings, statistical significances, or detailed outcomes regarding NNC0090-2746's performance in Type 2 Diabetes participants are not available in this abstract.